HUP0201222A3 - Use of soluble constimulatory molecules to enhance immune responses - Google Patents
Use of soluble constimulatory molecules to enhance immune responsesInfo
- Publication number
- HUP0201222A3 HUP0201222A3 HU0201222A HUP0201222A HUP0201222A3 HU P0201222 A3 HUP0201222 A3 HU P0201222A3 HU 0201222 A HU0201222 A HU 0201222A HU P0201222 A HUP0201222 A HU P0201222A HU P0201222 A3 HUP0201222 A3 HU P0201222A3
- Authority
- HU
- Hungary
- Prior art keywords
- soluble
- immune responses
- enhance immune
- constimulatory molecules
- constimulatory
- Prior art date
Links
- 230000028993 immune response Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13294499P | 1999-05-06 | 1999-05-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0201222A2 HUP0201222A2 (en) | 2002-08-28 |
HUP0201222A3 true HUP0201222A3 (en) | 2004-07-28 |
Family
ID=22456295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0201222A HUP0201222A3 (en) | 1999-05-06 | 2000-05-05 | Use of soluble constimulatory molecules to enhance immune responses |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1181053A2 (en) |
JP (1) | JP2002544170A (en) |
KR (1) | KR20020001865A (en) |
CN (1) | CN1377279A (en) |
AU (1) | AU4825700A (en) |
BR (1) | BR0010711A (en) |
CA (1) | CA2373256A1 (en) |
CZ (1) | CZ20013964A3 (en) |
HK (1) | HK1041810A1 (en) |
HU (1) | HUP0201222A3 (en) |
IL (1) | IL146106A0 (en) |
NO (1) | NO20015396L (en) |
PL (1) | PL360915A1 (en) |
WO (1) | WO2000067788A2 (en) |
ZA (1) | ZA200109376B (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3521382B2 (en) | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | Cell surface molecules that mediate cell-cell adhesion and signal transduction |
US7112655B1 (en) | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
JP3871503B2 (en) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | Immune disease treatment |
JP4210454B2 (en) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | Inflammatory bowel disease treatment |
JP3597140B2 (en) | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | Human monoclonal antibody against costimulatory molecule AILIM and pharmaceutical use thereof |
JP4212278B2 (en) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | Graft rejection inhibitor |
EP1910387B1 (en) * | 2005-06-30 | 2016-11-16 | Eisai R&D Management Co., Ltd. | Compounds for preparing immunological adjuvant |
AU2006321890A1 (en) | 2005-12-08 | 2007-06-14 | University Of Louisville Research Foundation, Inc. | Methods and compositions for expanding T regulatory cells |
JP2009518427A (en) | 2005-12-08 | 2009-05-07 | ユニバーシティー オブ ルーイビル リサーチ ファンデーション,インコーポレーテッド | In vivo cell surface manipulation |
US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
EP2736537A4 (en) | 2011-07-29 | 2015-04-15 | Selecta Biosciences Inc | Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses |
US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
EP2834356A4 (en) * | 2012-04-02 | 2015-09-02 | Univ Arizona | Recombinant bacterium for induction of cellular immune response |
US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
WO2015063616A2 (en) | 2013-11-04 | 2015-05-07 | Uti Limited Partnership | Methods and compositions for sustained immunotherapy |
MX2017014199A (en) | 2015-05-06 | 2018-03-28 | Uti Lp | Nanoparticle compositions for sustained therapy. |
CN110743006B (en) * | 2019-11-22 | 2020-08-25 | 北京启辰生生物科技有限公司 | Composition for synergistically relieving immune cell failure and application |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2207278T3 (en) * | 1998-07-28 | 2004-05-16 | Micromet Ag | HETEROMINICBODIES. |
-
2000
- 2000-05-05 WO PCT/US2000/012435 patent/WO2000067788A2/en not_active Application Discontinuation
- 2000-05-05 JP JP2000616813A patent/JP2002544170A/en not_active Withdrawn
- 2000-05-05 CN CN00810038A patent/CN1377279A/en active Pending
- 2000-05-05 CA CA002373256A patent/CA2373256A1/en not_active Abandoned
- 2000-05-05 PL PL36091500A patent/PL360915A1/en not_active Application Discontinuation
- 2000-05-05 BR BR0010711-5A patent/BR0010711A/en not_active Application Discontinuation
- 2000-05-05 AU AU48257/00A patent/AU4825700A/en not_active Abandoned
- 2000-05-05 EP EP00930437A patent/EP1181053A2/en not_active Withdrawn
- 2000-05-05 HU HU0201222A patent/HUP0201222A3/en unknown
- 2000-05-05 IL IL14610600A patent/IL146106A0/en unknown
- 2000-05-05 KR KR1020017014170A patent/KR20020001865A/en not_active Application Discontinuation
- 2000-05-05 CZ CZ20013964A patent/CZ20013964A3/en unknown
-
2001
- 2001-11-05 NO NO20015396A patent/NO20015396L/en not_active Application Discontinuation
- 2001-11-14 ZA ZA200109376A patent/ZA200109376B/en unknown
-
2002
- 2002-03-26 HK HK02102335.8A patent/HK1041810A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR0010711A (en) | 2002-02-13 |
PL360915A1 (en) | 2004-09-20 |
AU4825700A (en) | 2000-11-21 |
KR20020001865A (en) | 2002-01-09 |
HUP0201222A2 (en) | 2002-08-28 |
WO2000067788A2 (en) | 2000-11-16 |
JP2002544170A (en) | 2002-12-24 |
CA2373256A1 (en) | 2000-11-16 |
CZ20013964A3 (en) | 2002-06-12 |
NO20015396L (en) | 2002-01-02 |
WO2000067788A3 (en) | 2001-04-05 |
ZA200109376B (en) | 2003-03-13 |
CN1377279A (en) | 2002-10-30 |
EP1181053A2 (en) | 2002-02-27 |
IL146106A0 (en) | 2002-07-25 |
HK1041810A1 (en) | 2002-07-26 |
NO20015396D0 (en) | 2001-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0201222A2 (en) | Use of soluble constimulatory molecules to enhance immune responses | |
HK1061403A1 (en) | ANTIBODIES TO HUMAN IL-1ß | |
IL144578A0 (en) | Antibodies specific to kdr and uses thereof | |
HUP0200898A2 (en) | Derivatives of venlafaxine and methods of preparing and using the same | |
AU1449401A (en) | Method using prior activities to improve the completion of transaction | |
HUP0302352A3 (en) | Sn-38 lipid complexes and methods of use | |
AU2002228890A1 (en) | Use of zwitterionic polysaccharides for the specific modulation of immune processes | |
AU8390301A (en) | Antibodies to human MCP-1 | |
IL149614A0 (en) | Novel use of antibodies as vaccines | |
HUP0201642A3 (en) | Preparation of substituted piperidin-4-ones | |
HK1044817A1 (en) | Use of 13c-nmr to detect binding | |
GB0029847D0 (en) | Preparation of spheroids | |
ID25939A (en) | EQUIPMENT TO PRODUCE SMALL FOOD | |
AU3179999A (en) | Methods to treat undesirable immune responses | |
IL157614A0 (en) | Uses of opg ligand to modulate immune responses | |
AU2002249917A1 (en) | Induction of immune responses to isoaspartyl-modified antigens | |
AU5878600A (en) | Novel chitosan-containing liquid compositions and methods for their preparation and use | |
IL142069A0 (en) | Methods of downmodulating the immune response to therapeutic proteins | |
AU5801398A (en) | The use of cd4-binding small molecules to inhibit immune responses | |
AU6019599A (en) | Use of mcrp to enhance immune responses | |
AUPP942099A0 (en) | Improvements to cooking apparatus | |
GB9929873D0 (en) | Improvements in or relating to the reception of spread spectrum signals | |
AU4332900A (en) | Use of interleukin-11 to treat gastrointestinal disorders | |
AU6074000A (en) | Human immune response molecules | |
IL148351A0 (en) | Therapeutic immune condition compositions and methods |